S
Sylvie Negrier
Researcher at University of Lyon
Publications - 290
Citations - 30574
Sylvie Negrier is an academic researcher from University of Lyon. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 59, co-authored 275 publications receiving 28316 citations. Previous affiliations of Sylvie Negrier include French Institute of Health and Medical Research & Lyons.
Papers
More filters
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more
TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini,Bernard Escudier,Piotr Tomczak,Andrey Kaprin,Cezary Szczylik,Thomas E. Hutson,M. Dror Michaelson,Vera Gorbunova,Martin Gore,Igor G. Rusakov,Sylvie Negrier,Yen Chuan Ou,Daniel Castellano,Ho Yeong Lim,Hirotsugu Uemura,Jamal Tarazi,David Cella,Connie Chen,Brad Rosbrook,Sinil Kim,Robert J. Motzer +20 more
TL;DR: Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma and resulted in significantly longer progression-free survival (PFS) compared with sorafenib.
Journal ArticleDOI
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer,Konstantin Penkov,John B. A. G. Haanen,Brian I. Rini,Laurence Albiges,Matthew T. Campbell,Balaji Venugopal,Christian Kollmannsberger,Sylvie Negrier,Motohide Uemura,Jae L. Lee,Aleksandr Vasiliev,Wilson H. Miller,Howard Gurney,Manuela Schmidinger,James Larkin,Michael B. Atkins,Jens Bedke,Boris Alekseev,Jing Wang,Mariangela Mariani,Paul B. Robbins,Aleksander Chudnovsky,Camilla Fowst,Subramanian Hariharan,Bo Huang,Alessandra di Pietro,Toni K. Choueiri +27 more
TL;DR: Progression‐free survival was significantly longer with avelumab plus axitinib than with sunit inib among patients who received these agents as first‐line treatment for advanced renal‐cell carcinoma.